Immunocore Holdings (IMCR) Net Income towards Common Stockholders Growth (3y) (2024 - 2026)

Immunocore Holdings (IMCR) Net Income towards Common Stockholders Growth (3y) (2024 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 45.47%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -3.84%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 91.31%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Immunocore Holdings 1.72 Bn 878.48 Mn 106.24 Mn 38.67%

Historic Data

Download Data
DateValue
Mar 31, 2026 38.67%
Dec 31, 2025 -0.21%
Sep 30, 2025 -26.55%
Jun 30, 2025 19.42%
Dec 31, 2024 23.50%
Sep 30, 2024 30.26%